Kestra Medical Technologies Reports Preliminary Second Quarter Fiscal 2026 Financial Results

Rhea-AI Summary

Kestra Medical Technologies (Nasdaq: KMTS) reported preliminary Q2 fiscal 2026 results for the quarter ended October 31, 2025, showing continued commercial momentum in the wearable defibrillator market. Revenue is expected to be $22.2–$22.6M, up ~52% at the midpoint versus prior year. Gross profit is expected to be $11.0–$11.4M and gross margin is expected near 50.0% versus 39.6% prior year. Loss from operations is expected to be $31.6–$32.0M. Cash and cash equivalents are expected to be approximately $175M. Results are preliminary and subject to adjustment; final results will appear in the Form 10-Q filed in December 2025.

Positive

• Revenue expected +52% year-over-year at midpoint
• Gross margin expected improving to 50.0% from 39.6%
• Gross profit expected roughly doubled versus prior year
• Cash and cash equivalents expected ~ $175 million

Negative

• Loss from operations expected ~ $31.6–$32.0 million, up materially
• Operating loss increase versus prior year may pressure near-term profitability

News Market Reaction – KMTS

-8.49%

16 alerts

-8.49% News Effect

+6.0% Peak Tracked

-8.5% Trough Tracked

-$124M Valuation Impact

$1.33B Market Cap

1.1x Rel. Volume

On the day this news was published, KMTS declined 8.49%, reflecting a notable negative market reaction. Argus tracked a peak move of +6.0% during that session. Argus tracked a trough of -8.5% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $124M from the company's valuation, bringing the market cap to $1.33B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Q2 FY26 revenue: $22.2–$22.6M Q2 FY26 gross profit: $11.0–$11.4M Q2 FY26 gross margin: 50.0% +2 more

5 metrics

Q2 FY26 revenue $22.2–$22.6M Preliminary, quarter ended Oct 31, 2025; up 52% vs $14.7M prior year

Q2 FY26 gross profit $11.0–$11.4M Preliminary, vs $5.8M in prior year period

Q2 FY26 gross margin 50.0% Preliminary, vs 39.6% in prior year period

Q2 FY26 loss from operations $31.6–$32.0M Preliminary, vs $19.1M in prior year period

Cash and cash equivalents $175M Preliminary balance as of Oct 31, 2025

Market Reality Check

Price: $19.08 Vol: Volume 329,391 is below t...

normal vol

$19.08 Last Close

Volume Volume 329,391 is below the 20-day average of 375,225 (relative volume 0.88). normal

Technical Price $24.91 is trading above the 200-day MA $21.57, showing a pre-news uptrend.

Peers on Argus

KMTS slipped 0.89% while key peers were mixed: EMBC up 2.58%, PLSE down 3.37%, S...

1 Up

KMTS slipped 0.89% while key peers were mixed: EMBC up 2.58%, PLSE down 3.37%, STAA down 2.33%. Pre-news action appeared stock-specific rather than sector-driven.

Historical Context

5 past events · Latest: Dec 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 03	Earnings date set	Neutral	+12.2%	Announcement of upcoming Q2 FY26 earnings call and webcast logistics.
Dec 02	Equity offering priced	Negative	-6.8%	Pricing of upsized primary share offering with substantial gross proceeds.
Dec 01	Equity offering launch	Negative	-8.5%	Proposed primary offering to fund commercialization and R&D initiatives.
Dec 01	Prelim Q2 earnings	Positive	-8.5%	Preliminary Q2 FY26 results with strong revenue growth and margin expansion.
Nov 10	Clinical study data	Positive	+0.8%	Large ACE-PAS real-world study confirming ASSURE’s safety and effectiveness.

Pattern Detected

Earnings and fundamental updates often drew strong reactions, mostly aligned with news tone, but the latest preliminary earnings showed a negative divergence despite positive fundamentals.

Recent Company History

Over recent months, Kestra reported rapid revenue growth and expanding gross margins, alongside sizable operating losses. Prior earnings releases on Apr 14, 2025, Jul 15, 2025, and Sep 11, 2025 all highlighted strong top-line expansion and margin gains, typically met with positive or mixed price moves. More recently, large ACE-PAS study data supported ASSURE’s effectiveness, while December 2025 brought a dilutive share offering. Today’s preliminary Q2 FY26 update fits the pattern of high growth and improving margins but widening operating losses.

Market Pulse Summary

The stock moved -8.5% in the session following this news. A negative reaction despite robust prelimi...

Analysis

The stock moved -8.5% in the session following this news. A negative reaction despite robust preliminary revenue growth above 50% and gross margin near 50.0% fits a pattern where investors focus on sizable operating losses. The expected loss from operations of about $31.6–$32.0M is larger than the prior year, which may raise concerns about the path to profitability. Prior equity offerings could further weigh on sentiment if investors worry about continued capital needs even amid strong top-line performance.

Key Terms

wearable defibrillator, gross margin, loss from operations, cash and cash equivalents, +1 more

5 terms

wearable defibrillator medical

"Kestra grows and penetrates the wearable defibrillator market"

A wearable defibrillator is a lightweight medical device worn around the chest that continuously monitors the heart and automatically delivers an electric shock if a life‑threatening abnormal heartbeat is detected. Think of it as a mobile emergency responder that watches a person’s heart and intervenes only when needed. Investors care because demand, regulatory approvals, reimbursement rules, and device performance determine sales potential, clinical adoption, and company risk exposure.

gross margin financial

"meaningful improvement in our gross margin, a result of the attractive unit economics"

Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.

loss from operations financial

"Loss from operations is expected to be $31.6 to $32.0 million"

Loss from operations is the money a company loses from its main business activities, like selling products or services, before considering other expenses or income. It shows whether the company's core business is making or losing money. This figure matters because it helps investors understand if the business is running efficiently or struggling to earn enough to cover its costs.

cash and cash equivalents financial

"Cash and cash equivalents are expected to be approximately $175 million"

Cash and cash equivalents are the money a company has on hand plus very short-term, low-risk investments that can be quickly turned into cash, like bank deposits or government bills. Investors watch this figure because it shows a company’s immediate ability to pay bills, cover unexpected costs, and fund operations or growth — like a household’s checking account and emergency fund that keeps daily life running smoothly.

Form 10-Q regulatory

"in its quarterly report on Form 10-Q for the second quarter"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

AI-generated analysis. Not financial advice.

KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported preliminary financial results for the second quarter fiscal 2026 ended October 31, 2025.

“Revenue is expected to grow by over 50% in the second quarter and continues to exceed our FY26 plan, reflecting sustained commercial momentum as Kestra grows and penetrates the wearable defibrillator market,” said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. “In addition to our commercial execution, we are encouraged by the meaningful improvement in our gross margin, a result of the attractive unit economics and positive leverage inherent in our business model.”

Preliminary Second Quarter Fiscal 2026 Financial Results

• Revenue is expected to be $22.2 to $22.6 million, an increase of 52% at the midpoint compared to $14.7 million in the prior year period.

• Gross profit is expected to be $11.0 to $11.4 million compared to $5.8 million in the prior year period.
   
  • Based on the midpoints of expected revenue and gross profit, gross margin is expected to be 50.0% compared to 39.6% in the prior year period.

• Loss from operations is expected to be $31.6 to $32.0 million compared to $19.1 million in the prior year period.

• Cash and cash equivalents are expected to be approximately $175 million.
  

These results are preliminary estimates and remain subject to adjustment. These preliminary estimated results should not be viewed as a substitute for financial statements prepared in accordance with U.S. generally accepted accounting principles. Kestra will provide complete financial results in its earnings release and in its quarterly report on Form 10-Q for the second quarter ended October 31, 2025 to be filed in December.

Forward-Looking Statements
Except where otherwise noted, the information contained in this press release is as of December 1, 2025. Statements in this press release that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, the Kestra’s preliminary estimated financial results for the fiscal quarter ended October 31, 2025, which are preliminary unaudited estimates that are subject to significant uncertainties. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; and other risks and uncertainties, including those described under the heading “Risk Factors” in Kestra’s Annual Report on Form 10-K for the fiscal year ended April 30, 2025 filed with the U.S. Securities and Exchange Commission (“SEC”) on July 17, 2025, and in other periodic reports filed by Kestra with the SEC. These filings, when made, are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/.

About Kestra
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com.

Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com

FAQ

What revenue did Kestra Medical Technologies (KMTS) preliminarily report for Q2 fiscal 2026?

Preliminary revenue is expected to be $22.2–$22.6 million for Q2 fiscal 2026 (quarter ended Oct 31, 2025).

How much did Kestra (KMTS) preliminary revenue increase year-over-year in Q2 fiscal 2026?

At the midpoint, preliminary revenue represents an approximate 52% year-over-year increase versus the prior year period.

What preliminary gross margin did Kestra (KMTS) report for Q2 fiscal 2026 and how does it compare to last year?

Preliminary gross margin is expected to be 50.0%, up from 39.6% in the prior year period.

What is Kestra's (KMTS) expected operating loss for Q2 fiscal 2026?

Loss from operations is expected to be approximately $31.6–$32.0 million for the quarter.

How much cash did Kestra (KMTS) report it expects to hold after Q2 fiscal 2026?

Kestra expects cash and cash equivalents to be approximately $175 million as of the preliminary estimate.

When will Kestra (KMTS) release final Q2 fiscal 2026 results and file the Form 10-Q?

Kestra will provide complete financial results and file its Form 10-Q in December 2025 for the quarter ended October 31, 2025.